NCT07333274 2026-01-12
Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma
Shandong Cancer Hospital and Institute
Phase 3 Recruiting
Clinical Trials
8 trialsNCT06509009 2025-09-19
Nimotuzumab Combined With TGP as First-line Therapy in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT07070479 2025-09-18
Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial
Sun Yat-sen University
Phase 2 Recruiting
NCT06912711 2025-05-21
TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2 Recruiting
NCT06259721 2024-03-07
Anti-PD1 Monoclonal Antibody Combined With Nimotuzumab and Capecitabine in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma
Jiangxi Provincial Cancer Hospital
Phase 2 Recruiting
NCT06026878 2023-09-07
GNT Induction Treatment in Locally Advanced NPC
Air Force Military Medical University, China
Phase 3 Recruiting
NCT05772208 2023-03-16
Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant Chemotherapy
Fudan University
Phase 3 Recruiting
NCT05717790 2023-02-08
Concurrent and Adjuvant Nimotuzumab Combined With Induction Chemotherapy Plus Chemoradiation in Nasopharyngeal Carcinoma
Fourth Affiliated Hospital of Guangxi Medical University
Phase NA Recruiting